Merk And Daiichi Sankyo JV Receives FDA Priority Review For Ifinatamab Deruxtecan For The Treatment Of Adult Patients With Extensive-Stage Small Cell Lung Cancer

Benzinga Newsdesk www.benzinga.com Neutral 60.0%

Neg 0% Neu 60% Pos 0%

Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck.